Riot Platforms 株価情報 (NASDAQ: RIOT)

最新ニュース Riot Platforms (NASDAQ:RIOT) 株価情報

Riot Platforms

Riot Platforms Inc is a vertically integrated Bitcoin mining company focused on building, supporting, and operating blockchain technologies. The company's segments include Bitcoin Mining and Engineering. The Bitcoin Mining segment generates revenue from the Bitcoin the Company earns through its Bitcoin Mining activities. The Engineering segment generates revenue through customer contracts for custom engineered electrical products. It generates the majority of its revenue from the Bitcoin Mining segment.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Markets

$BTC

BITF

RIOT

最近、ビットコイン（仮想通貨：BTC）マイニング会社ライオットプラットフォーム（NASDAQ:RIOT）は、ライバル企業ビットファーム（NASDAQ:BITF）に対する持ち株比率を12%に引き上げました。

ライオットプラットフォームがビットファームの持ち株比率増加

Riot Platforms Inc

VGS, The World's Leader in Tokenization, is proud to announce an expansion of its successful, long-term partnership with Visa. Building on years of product partnership and shared achievements, VGS will be a preferred pilot partner with Visa through the Visa Intelligent Commerce program, helping to pioneer the future of AI commerce. Today, VGS powers 4.5B tokens globally, many of which are Visa cards, for some of the largest platforms, merchants, FIs, and fintechs in the world. Now, our long-standing strategic partnership for payments tokenization is evolving into foundational infrastructure to enable AI and Agent-driven commerce experiences, an emerging ecosystem often called Agentic Commerce. This evolution signifies a strengthened commitment from both organizations to leverage their respective strengths and expertise to deliver even greater and more secure payment outcomes for all commerce participants, from Merchants to Developers to Fintechs of all types around the world.

VGS Expands Long-Term Partnership With Visa To Pioneer Future Of AI Commerce

<a href="https://www.mdpi.com/1424-8220/25/9/2832" title="https://www.mdpi.com/1424-8220/25/9/2832">https://www.mdpi.com/1424-8220/25/9/2832</a>

Biotech

Trading Ideas

General

Watching Know Labs; Traders Circulate Social Media Post Saying MDPI journal article out today about a Know Labs' experiment using their sensor technology to measure pH changes in a liquid without making contact with the liquid with 100% accuracy. "Contactless Detection of pH Change in a Liquid Analyte"

RBC Capital analyst Shagun Singh maintains Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) with a Sector Perform and lowers the price target from $5 to $4.

Price Target

Analyst Ratings

ZYXI

RBC Capital Maintains Sector Perform on Zynex, Lowers Price Target to $4

Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) shares fell 2.44% to $540.91 on Wednesday ahead of its first-quarter earnings report, pressured in part by Snap Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) <a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/45113655/snap-stock-is-getting-smoked-on-wednesday-whats-going-on">results</a> the evening prior.
What To Know: While Snap beat Wall Street estimates on revenue and losses per share, concerns emerged from its cautious outlook and lack of formal second-quarter guidance, reigniting fears about a broader slowdown in digital advertising. 
Investors may worry that Snap&#8217;s advertising headwinds could signal challenges for Meta as well, particularly given overlapping advertiser bases and reliance on macroeconomic ad trends.
Read Also: <a href="https://www.benzinga.com/news/25/04/45103964/pinterest-pins-stock-falls-after-snap-earnings-spark-digital-ad-concerns">Pinterest Stock Falls After Snap Earnings Spark Digital Ad Concerns</a>
Meta Earnings Up Next: Meta, which has a stronger ad infrastructure and broader platform reach than Snap—including Facebook, Instagram and WhatsApp—is <a href="https://www.benzinga.com/general/social-media/25/04/45083272/meta-platforms-q1-earnings-preview-analyst-expects-weak-guidance-will-company-continue-streak-of-revenue-beats">expected to report</a> revenue of $41.39 billion and EPS of $5.28. 
However, uncertainty around capital spending, <a href="https://www.benzinga.com/tech/25/04/45112477/exclusive-if-meta-is-forced-to-divest-instagram-whatsapp-or-facebook-43-pick-this-standout">litigation pressures</a> and a possible decline in user engagement—highlighted during recent FTC testimony by CEO Mark Zuckerberg—may weigh on sentiment. Investors will be watching closely for updates on Meta's AI initiatives, monetization of Instagram and WhatsApp, and commentary on ad demand. 
Meta&#8217;s first-ever GenAI developer event and launch of a standalone Meta AI app signal ambitious long-term bets that will need to prove traction in a cautious ad market.
Read Also: <a href="https://www.benzinga.com/government/regulations/25/04/45111682/wall-street-falls-on-weak-economic-data-as-oil-slumps-to-58-whats-driving-markets-wednesday">Wall Street Falls On Weak Economic Data As Oil Slumps To $58: What&#8217;s Driving Markets Wednesday</a>
<h2 class="wp-block-heading">How To Buy META Stock</h2>
By now you're likely curious about how to participate in the market for Meta Platforms &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Meta Platforms, which is trading at $540.91 as of publishing time, $100 would buy you about 0.18 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, META has a 52-week high of $740.89 and a 52-week low of $427.20.

SNAP

Meta Platforms Stock Drops Ahead Of Earnings As Snap Results Raise Digital Ad Concerns

RBC Capital analyst Deane Dray maintains Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) with a Outperform and raises the price target from $143 to $147.

RBC Capital Maintains Outperform on Xylem, Raises Price Target to $147

Corpay Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAY#NYSE">CPAY</a>) stock slipped after the company announced a strategic partnership with Mastercard Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) in cross-border payments.
The partnership "validates the hidden value of Corpay's B2B cross-border payments unit," according to JPMorgan.
The Partnership: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58f777c10bd99100018a435e/tien-tsin-huang">Analyst Tien-tsin Huang</a> said that the agreement has Mastercard taking an investment stake of $300 million in Corpay's cross-border business, which is an "important growth area in payments."
The Corpay Thesis: The deal will allow Mastercard's non-tier 1 banks to better compete with tier 1 banks by enabling them to provide cross-border payments to financial institutions (FIs), Huang said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
This would accelerate Corpay's cross-border revenues from the underserved FI segment, he added.
"Also, CPAY will exclusively issue Mastercard virtual cards, while CPAY will re-market Mastercard Move to its current/ prospective SME clients," the analyst wrote. The deal seems like it aligns the interests of both companies to penetrate the cross-border and business-to-business (B2B) markets, he further stated.
CPAY Price Action: Shares of Corpay had declined by 1.49% to $319.43 at the time of publication on Wednesday.
Read More: 
<ul>
<li><a href="https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=newssearch&amp;cd=&amp;cad=rja&amp;uact=8&amp;ved=2ahUKEwj2hvfI_fqMAxXER2wGHWLEOIsQxfQBKAB6BAgJEAE&amp;url=https%3A%2F%2Fwww.benzinga.com%2Fnews%2Fearnings%2F25%2F04%2F44937938%2Fcapital-one-reports-mixed-q1-results-eps-beat-revenue-misses&amp;usg=AOvVaw3g8PTc3dpKR3V3BTnwdyaP&amp;opi=89978449">Mastercard Bets On Cross-Border Payments With $300 Million Corpay Deal</a></li>
</ul>
Image: Shutterstock

Financing

CPAY

Corpay Interests Align Well With Mastercard: Analyst

RBC Capital analyst Sabahat Khan maintains Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) with a Sector Perform and raises the price target from $227 to $229.

RBC Capital Maintains Sector Perform on Waste Management, Raises Price Target to $229

RBC Capital analyst Ben Hendrix maintains Universal Health Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) with a Sector Perform and lowers the price target from $211 to $201.

RBC Capital Maintains Sector Perform on Universal Health Services, Lowers Price Target to $201

RBC Capital analyst Nik Modi maintains Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) with a Outperform and raises the price target from $73 to $76.

RBC Capital Maintains Outperform on Coca-Cola, Raises Price Target to $76

Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) will release its quarterly earnings report on Thursday, 2025-05-01. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Travere Therapeutics to report an earnings per share (EPS) of $-0.36.
The market awaits Travere Therapeutics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
Last quarter the company missed EPS by $0.09, which was followed by a 6.79% drop in the share price the next day.
Here's a look at Travere Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.38</td>
<td>-0.68</td>
<td>-0.86</td>
<td>-0.99</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.47</td>
<td>-0.46</td>
<td>-0.65</td>
<td>-1.51</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-7.000000000000001%</td>
<td>0.0%</td>
<td>-3.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746039781_0.png" alt="eps graph" />
<h3>Travere Therapeutics Share Price Analysis</h3>
Shares of Travere Therapeutics were trading at $20.08 as of April 29. Over the last 52-week period, shares are up 236.04%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/TVTX/earnings">To track all earnings releases for Travere Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

TVTX

Travere Therapeutics's Earnings: A Preview

LendingTree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) will release its quarterly earnings report on Thursday, 2025-05-01. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate LendingTree to report an earnings per share (EPS) of $0.65.
The market awaits LendingTree's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Past Earnings Performance</h3>
The company's EPS beat by $0.63 in the last quarter, leading to a 22.52% increase in the share price on the following day.
Here's a look at LendingTree's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.53</td>
<td>0.66</td>
<td>0.46</td>
<td>0.36</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.16</td>
<td>0.80</td>
<td>0.54</td>
<td>0.70</td>
</tr>
<tr>
<td>Price Change %</td>
<td>23.0%</td>
<td>-21.0%</td>
<td>2.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746039773_0.png" alt="eps graph" />
<h3>Tracking LendingTree's Stock Performance</h3>
Shares of LendingTree were trading at $53.02 as of April 29. Over the last 52-week period, shares are up 4.22%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Insights Shared by Analysts on LendingTree</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on LendingTree.
With 4 analyst ratings, LendingTree has a consensus rating of Outperform. The average one-year price target is $67.0, indicating a potential 26.37% upside.
<h3>Peer Ratings Overview</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of and Nerdwallet, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Nerdwallet, with an average 1-year price target of $14.0, suggesting a potential 73.59% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
In the peer analysis summary, key metrics for and Nerdwallet are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>LendingTree</td>
<td>Outperform</td>
<td>94.65%</td>
<td>$251.78M</td>
<td>7.39%</td>
</tr>
<tr>
<td>Nerdwallet</td>
<td>Neutral</td>
<td>37.47%</td>
<td>$167.10M</td>
<td>11.24%</td>
</tr>
</tbody>
</table>

Key Takeaway:
LendingTree ranks higher in Revenue Growth compared to its peers. It also has a lower Gross Profit margin. However, its Return on Equity is lower than the peer average. Overall, LendingTree is positioned in the middle among its peers based on the provided metrics.
<h3>All You Need to Know About LendingTree</h3>
LendingTree Inc. is a U.S.-based company that mainly operates an online loan marketplace. The company offers online tools and resources to help consumers find loans or other credit-based products, including mortgage loans, reverse mortgages, home equity loans, personal loans, auto loans, credit cards, student loans, small business loans, and various related products. It provides consumers with direct access to a wide array of lenders. The company has three reportable segments: Home, Consumer, and Insurance. It generates match fees by connecting consumers with lenders and closing fees from lenders when a transaction is finalized. The company conducts business solely in the United States.
<h3>Key Indicators: LendingTree's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: LendingTree displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 94.65%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: LendingTree's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 2.87%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): LendingTree's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 7.39%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): LendingTree's ROA stands out, surpassing industry averages. With an impressive ROA of 0.97%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 5.0, LendingTree faces challenges in effectively managing its debt levels, indicating potential financial strain.
<a href="https://www.benzinga.com/quote/TREE/earnings">To track all earnings releases for LendingTree visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TREE

Preview: LendingTree's Earnings

Materion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTRN#NYSE">MTRN</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-01. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Materion to report an earnings per share (EPS) of $1.04.
Materion bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings Track Record</h3>
In the previous earnings release, the company missed EPS by $0.01, leading to a 3.39% drop in the share price the following trading session.
Here's a look at Materion's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.45</td>
<td>1.41</td>
<td>1.41</td>
<td>0.96</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.44</td>
<td>1.41</td>
<td>1.42</td>
<td>0.96</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>-3.0%</td>
<td>11.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746039763_0.png" alt="eps graph" />
<h3>Market Performance of Materion's Stock</h3>
Shares of Materion were trading at $83.16 as of April 29. Over the last 52-week period, shares are down 24.96%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/MTRN/earnings">To track all earnings releases for Materion visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MTRN

Earnings Preview: Materion

MGP Ingredients (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGPI#NASDAQ">MGPI</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release.
Analysts are estimating that MGP Ingredients will report an earnings per share (EPS) of $0.37.
Investors in MGP Ingredients are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Performance in Previous Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.07, leading to a 3.23% increase in the share price on the subsequent day.
Here's a look at MGP Ingredients's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.50</td>
<td>1.25</td>
<td>1.56</td>
<td>0.98</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.57</td>
<td>1.29</td>
<td>1.71</td>
<td>1.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-5.0%</td>
<td>-1.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746039756_0.png" alt="eps graph" />
<h3>Performance of MGP Ingredients Shares</h3>
Shares of MGP Ingredients were trading at $29.55 as of April 29. Over the last 52-week period, shares are down 64.16%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analyst Opinions on MGP Ingredients</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding MGP Ingredients.
Analysts have given MGP Ingredients a total of 3 ratings, with the consensus rating being Buy. The average one-year price target is $39.0, indicating a potential 31.98% upside.
<h3>Peer Ratings Comparison</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of and MGP Ingredients, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<h3>Peer Metrics Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for and MGP Ingredients, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>MGP Ingredients</td>
<td>Buy</td>
<td>-15.87%</td>
<td>$74.47M</td>
<td>-4.75%</td>
</tr>
</tbody>
</table>

Key Takeaway:
MGP Ingredients ranks at the bottom for Revenue Growth among its peers. It also ranks at the bottom for Gross Profit. Additionally, it is at the bottom for Return on Equity. Overall, MGP Ingredients is positioned at the bottom compared to its peers across all key metrics.
<h3>Unveiling the Story Behind MGP Ingredients</h3>
MGP Ingredients Inc is a producer and supplier of premium distilled spirits and specialty wheat protein and starch food ingredients. MGP also produces high-quality industrial alcohol for use in both food and non-food applications. It operates in three segments: Distillery Solutions, Branded Spirits Segment, and Ingredient Solutions. Distillery Solutions provides distillery co-products, such as distillers feed, fuel grade alcohol, and corn oil: and warehouse services, including barrel put away, storage, and retrieval services. It derives its revenue from the Distillery Solutions segment.
<h3>Key Indicators: MGP Ingredients's Financial Health</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: MGP Ingredients's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -15.87%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -22.96%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): MGP Ingredients's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -4.75% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): MGP Ingredients's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -2.92%, the company showcases efficient use of assets and strong financial health.
Debt Management: MGP Ingredients's debt-to-equity ratio is below the industry average. With a ratio of 0.41, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/MGPI/earnings">To track all earnings releases for MGP Ingredients visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MGPI

Preview: MGP Ingredients's Earnings

Mercer Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MERC#NASDAQ">MERC</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Mercer Intl will report an earnings per share (EPS) of $-0.19.
The market awaits Mercer Intl's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company beat EPS by $0.20, leading to a 16.87% increase in the share price the following trading session.
Here's a look at Mercer Intl's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.05</td>
<td>0.08</td>
<td>-0.31</td>
<td>-0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.25</td>
<td>-0.26</td>
<td>-1.01</td>
<td>-0.25</td>
</tr>
<tr>
<td>Price Change %</td>
<td>17.0%</td>
<td>-0.0%</td>
<td>0.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746039748_0.png" alt="eps graph" />
<h3>Mercer Intl Share Price Analysis</h3>
Shares of Mercer Intl were trading at $4.61 as of April 29. Over the last 52-week period, shares are down 86.96%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analysts' Perspectives on Mercer Intl</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Mercer Intl.
The consensus rating for Mercer Intl is Neutral, based on 1 analyst ratings. With an average one-year price target of $6.0, there's a potential 30.15% upside.
<h3>Analyzing Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Clearwater Paper, Magnera and Sylvamo, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Clearwater Paper, with an average 1-year price target of $37.0, suggesting a potential 702.6% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Magnera, with an average 1-year price target of $24.0, suggesting a potential 420.61% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Sylvamo, with an average 1-year price target of $80.0, suggesting a potential 1635.36% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
In the peer analysis summary, key metrics for Clearwater Paper, Magnera and Sylvamo are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mercer Intl</td>
<td>Neutral</td>
<td>3.81%</td>
<td>$76.18M</td>
<td>3.53%</td>
</tr>
<tr>
<td>Clearwater Paper</td>
<td>Outperform</td>
<td>44.12%</td>
<td>$14.70M</td>
<td>26.21%</td>
</tr>
<tr>
<td>Magnera</td>
<td>Outperform</td>
<td>119.11%</td>
<td>$71M</td>
<td>-9.14%</td>
</tr>
<tr>
<td>Sylvamo</td>
<td>Neutral</td>
<td>0.62%</td>
<td>$237M</td>
<td>9.08%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Mercer Intl ranks at the bottom for Revenue Growth and Gross Profit among its peers. It is in the middle for Return on Equity.
<h3>Delving into Mercer Intl's Background</h3>
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.
<h3>A Deep Dive into Mercer Intl's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Mercer Intl showcased positive performance, achieving a revenue growth rate of 3.81% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Mercer Intl's net margin excels beyond industry benchmarks, reaching 3.42%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Mercer Intl's ROE stands out, surpassing industry averages. With an impressive ROE of 3.53%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Mercer Intl's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.7%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 3.47, Mercer Intl faces challenges in effectively managing its debt levels, indicating potential financial strain.
<a href="https://www.benzinga.com/quote/MERC/earnings">To track all earnings releases for Mercer Intl visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MERC

Insights Ahead: Mercer Intl's Quarterly Earnings

RBC Capital analyst Ben Hendrix maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Outperform and raises the price target from $183 to $189.

RBC Capital Maintains Outperform on Tenet Healthcare, Raises Price Target to $189

Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Kura Oncology will report an earnings per share (EPS) of $-0.60.
Anticipation surrounds Kura Oncology's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS beat by $0.42, leading to a 1.54% drop in the share price on the subsequent day.
Here's a look at Kura Oncology's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.64</td>
<td>-0.63</td>
<td>-0.63</td>
<td>-0.55</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.22</td>
<td>-0.63</td>
<td>-0.59</td>
<td>-0.59</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746039736_0.png" alt="eps graph" />
<h3>Market Performance of Kura Oncology's Stock</h3>
Shares of Kura Oncology were trading at $6.52 as of April 29. Over the last 52-week period, shares are down 68.21%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/KURA/earnings">To track all earnings releases for Kura Oncology visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KURA

Uncovering Potential: Kura Oncology's Earnings Preview

Mobile learning platform Duolingo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) has <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45093631/duolingo-launches-148-new-language-courses-expands-access-to-popular-languages-including-japanese-" rel="noreferrer noopener">introduced its most extensive </a>course expansion to date, launching 148 new language programs on its platform.
This substantial growth more than doubles its existing offerings. The launch makes Duolingo's top seven non-English languages, Spanish, French, German, Italian, Japanese, Korean, and Mandarin accessible across all 28 of its supported interface languages.
In the past, developing a single language course on Duolingo could take several years. But with the help of generative AI, enhanced internal tools, and a new shared content system, the company has shortened that process, rolling out its newest set of courses in less than a year.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/04/45040811/marriott-bets-355m-on-trendy-citizenm-hotels-to-woo-modern-travelers" rel="noreferrer noopener">Marriott Bets $355M On Trendy CitizenM Hotels To Woo Modern Travelers</a>
"Developing our first 100 courses took about 12 years, and now, in about a year, we're able to create and launch nearly 150 new courses. This is a great example of how generative AI can directly benefit our learners," said CEO and co-founder Luis von Ahn.
This shared content model enables the creation of a core course structure that can be quickly adapted for multiple languages.
The majority of the newly launched courses are designed for beginners, aligning with A1–A2 levels on the CEFR scale, and include interactive tools such as Stories and DuoRadio to help reading and listening comprehension.
Duolingo noted that higher-level content is expected to be added in the coming months.
The release is especially impactful in regions where access to non-English courses was previously limited. In Latin America, Spanish and Portuguese speakers now have access to Asian languages like Japanese, Mandarin, and Korean.
In Europe, learners speaking languages such as French, German, or Italian can also explore these new additions.
Meanwhile, in Asia, speakers of languages like Hindi, Thai, and Tamil can now learn any of the top seven languages, whereas previously, their options were largely restricted to English.
Price Action: DUOL shares traded higher by 0.35% at $386.48 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/04/45011895/the-future-of-flight-united-airlines-invests-in-radical-jet-design" target="_blank" rel="noreferrer noopener">The Future of Flight? United Airlines Invests In Radical Jet Design</a></li>
</ul>
Photo by DANIEL CONSTANTE via Shutterstock

Tech

DUOL

Duolingo Launches Its Biggest Expansion Yet With 148 New Courses

Xerox Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NASDAQ">XRX</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement.
Analysts estimate that Xerox Holdings will report an earnings per share (EPS) of $0.21. 
Anticipation surrounds Xerox Holdings's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
Last quarter the company missed EPS by $0.13, which was followed by a 5.79% drop in the share price the next day.
Here's a look at Xerox Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.49</td>
<td>0.51</td>
<td>0.43</td>
<td>0.35</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.36</td>
<td>0.25</td>
<td>0.29</td>
<td>0.06</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-6.0%</td>
<td>-3.0%</td>
<td>2.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746039719_0.png" alt="eps graph" />
<h3>Market Performance of Xerox Holdings's Stock</h3>
Shares of Xerox Holdings were trading at $4.44 as of April 29. Over the last 52-week period, shares are down 67.18%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/XRX/earnings">To track all earnings releases for Xerox Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What to Expect from Xerox Holdings's Earnings

Illinois Tool Works Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) stock was trading lower on Wednesday after the company reported better-than-expected <a href="https://www.benzinga.com/pressreleases/25/04/g45097281/itw-reports-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">first-quarter 2025 results</a>.
The company reported revenue of $3.84 billion, a 3.4% decline year over year, which aligns with the consensus estimate. EPS for the quarter stood at $2.38, down from $2.73 YoY and above the consensus of $2.36.
Organic revenue declined by 1.6%, while organic revenue remained nearly flat on an equal-day basis. Foreign currency translation had a negative impact of 1.8% on revenue.
Revenue By Segments: Automotive OEM $786 million (-3.7% YoY), Food Equipment $627 million (-0.7% YoY), Test &amp; Measurement and Electronics $652 million (-6.3% YoY), Welding $472 million (-0.9% YoY), Polymers &amp; Fluids $429 million (-0.8% YoY), Construction Products $443 million (-9.2% YoY) and Specialty Products $435 million (-1% YoY).
Operating income decreased 15.6% year over year to $951 million, and the operating margin contracted 360 bps to 24.8%. Enterprise initiatives contributed 120 basis points, offset by higher restructuring expenses from 80/20 projects and one-time items.
ITW&#8217;s operating cash flow was $592 million for the quarter, with free cash flow of $496 million, reflecting a 71% conversion to net income. The company repurchased $375 million of its shares during the quarter.
&#8220;Acknowledging the uncertain external environment, we are maintaining our full year 2025 guidance as we expect our ongoing pricing actions to offset tariff cost impacts. ITW is built to outperform in today&#8217;s volatile environment,&#8221; commented Christopher A. O&#8217;Herlihy, president and CEO.
&#8220;Our largely &#8216;produce where we sell&#8217; manufacturing strategy, decentralized operating culture which enables rapid &#8216;read and react&#8217; response, and diversified high-quality business portfolio all provide resilience during times of volatility and uncertainty. Our strong financial profile allows us to maintain our strategic investments and focus on driving continued progress on our long-term strategy to make above-market organic growth, fueled by Customer-back Innovation, into a core ITW strength,&#8221; O&#8217;Herlihy concluded.
2025 Guidance reaffirmed: ITW maintains its GAAP EPS guidance of $10.15 – $10.55 versus the consensus of $10.27.
Revenue and organic growth are projected to be 0-2%, with an operating margin expected between 26.5% and 27.5%.
The free cash flow is expected to exceed 100% of net income, and the company plans to repurchase $1.5 billion in shares. The projected effective tax rate is 24%.
Price Action: ITW shares traded lower by 3.58% at $233.10 at the last check Wednesday.
Photo: Shutterstock

Guidance

Illinois Tool Works Faces Q1 Revenue Dip And Lower EPS, Maintains 2025 Guidance Amid Uncertainty

LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) will release its quarterly earnings report on Thursday, 2025-05-01. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate LeMaitre Vascular to report an earnings per share (EPS) of $0.50.
The market awaits LeMaitre Vascular's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.00, which was followed by a 8.07% drop in the share price the next day.
Here's a look at LeMaitre Vascular's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.49</td>
<td>0.43</td>
<td>0.47</td>
<td>0.39</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.49</td>
<td>0.49</td>
<td>0.53</td>
<td>0.44</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-8.0%</td>
<td>7.000000000000001%</td>
<td>-1.0%</td>
<td>11.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746039689_0.png" alt="eps graph" />
<h3>Performance of LeMaitre Vascular Shares</h3>
Shares of LeMaitre Vascular were trading at $92.6 as of April 29. Over the last 52-week period, shares are up 34.81%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Take on LeMaitre Vascular</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on LeMaitre Vascular.
The consensus rating for LeMaitre Vascular is Buy, derived from 3 analyst ratings. An average one-year price target of $105.0 implies a potential 13.39% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of NovoCure, Enovis and QuidelOrtho, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for NovoCure, with an average 1-year price target of $29.67, suggesting a potential 67.96% downside.</li>
<li>Analysts currently favor an Buy trajectory for Enovis, with an average 1-year price target of $64.0, suggesting a potential 30.89% downside.</li>
<li>Analysts currently favor an Neutral trajectory for QuidelOrtho, with an average 1-year price target of $43.67, suggesting a potential 52.84% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
The peer analysis summary outlines pivotal metrics for NovoCure, Enovis and QuidelOrtho, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>LeMaitre Vascular</td>
<td>Buy</td>
<td>13.98%</td>
<td>$38.59M</td>
<td>3.35%</td>
</tr>
<tr>
<td>NovoCure</td>
<td>Neutral</td>
<td>11.91%</td>
<td>$116.47M</td>
<td>-9.50%</td>
</tr>
<tr>
<td>Enovis</td>
<td>Buy</td>
<td>23.29%</td>
<td>$307.52M</td>
<td>-23.87%</td>
</tr>
<tr>
<td>QuidelOrtho</td>
<td>Neutral</td>
<td>-4.69%</td>
<td>$326.10M</td>
<td>-5.78%</td>
</tr>
</tbody>
</table>

Key Takeaway:
LeMaitre Vascular ranks highest in Revenue Growth among its peers. It also leads in Gross Profit margin. However, it has the lowest Return on Equity. Overall, LeMaitre Vascular is positioned favorably compared to its peers in terms of financial performance.
<h3>About LeMaitre Vascular</h3>
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.
<h3>A Deep Dive into LeMaitre Vascular's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: LeMaitre Vascular's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 13.98%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: LeMaitre Vascular's net margin is impressive, surpassing industry averages. With a net margin of 20.07%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): LeMaitre Vascular's ROE excels beyond industry benchmarks, reaching 3.35%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): LeMaitre Vascular's ROA stands out, surpassing industry averages. With an impressive ROA of 2.41%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: LeMaitre Vascular's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.55.
<a href="https://www.benzinga.com/quote/LMAT/earnings">To track all earnings releases for LeMaitre Vascular visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LMAT

A Look at LeMaitre Vascular's Upcoming Earnings Report

Press Releases

Riot Platforms Announces Entry into Non-Binding Term Sheet to Acquire Certain Assets of Rhodium and Settlement Agreement

Tech Stocks See Historic Gains in 2024 Thanks to Crypto and AI

Riot Announces March 2025 Production and Operations Updates

Small Cap

RIOT PLATFORMS, INC. EARLY WARNING REPORT PRESS RELEASE REGARDING WAIVER AND IRREVOCABLE PROXY

Bitcoin Rebounds as Investors Seek Refuge from Tariff Onslaught

Amongst Volatility in The Markets, More Organizations Embrace Bitcoin, Adding Cryptocurrency to Their Treasury

Riot Announces First Quarter 2025 Earnings Conference Call

COEPTIS (COEP) Expands Global Footprint with Strategic India Tech Hub

Riot Platforms Announces $100 Million Credit Facility with Coinbase

Riot Platforms Announces Closing of the Acquisition of Rhodium Assets at the Rockdale Facility Following the Previously Announced Settlement Agreement

COEP

COIN

HOOD

KULR

MARA

MSTR

NVDA

PYPL

TSX:BITF

Agilysys

C3.ai

Alkami Technology

Alarm.com Holdings

Asana

AvePoint

BlackLine

Blackbaud

Braze

Bitdeer Technologies Group - Ordinary Shares

Bitdeer Technologies

Cleanspark

Sprinklr

Diginex

DoubleVerify Holdings

EverCommerce

Five9

Life360

Ncino

NextNav

Pony AI Inc. - American Depositary Shares

Pony AI

D-Wave Quantum

LiveRamp Holdings

RingCentral

Clear Secure

Zeta Global Holdings Corp. Class A Common Stock

Zeta Global Holdings

Piper Sandler

JP Morgan

Roth MKM

Cantor Fitzgerald

Needham

Riot Blockchain

Screenshot 2025-02-14 at 11.00.11 AM

CLSK

FUFU

How BitFuFu&#39;s 1GW Global Capacity Expansion Plan Can Help Move Crypto Into A New Landscape

Screenshot 2024-11-15 at 7.42.11 PM

BTDR

BitFuFu Posts Double-Digit Third Quarter Revenue Growth In A Challenging Market

Untitled design - 2024-08-30T174008.310

BitFuFu Posts 70% Revenue Growth And Outlines Strategic Expansion – Company Expects Continued Growth Amid Market Volatility

Screenshot 2024-06-26 at 5.30.28 PM

Three Bitcoin Players You May Want To Watch In The Next Potential Bull Cycle

Screenshot 2024-05-29 at 5.42.06 PM

BitFuFu Q1 Earnings: Adjusted EBITDA Up 430.9% To $49.4 Million On Revenue Growth Of 149%, Cash Position Rises To $163.7 Million

Screenshot 2024-04-12 at 5.28.51 PM

Bitdeer Releases Full-Year Results For 2023 – Revenue Up And Forecast For Continued Growth

Screenshot 2024-03-13 at 5.41.37 PM

Bitdeer Creates First-Generation Bitcoin Mining Chip In Major Step To Becoming The First Fully Integrated Miner

最近、ビットコイン（仮想通貨：<a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>）マイニング会社ライオットプラットフォーム（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>）は、ライバル企業ビットファーム（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BITF#NASDAQ">BITF</a>）に対する持ち株比率を12%に引き上げました。
出来事：ライオットプラットフォームはビットファーム約150万株を、1株あたり約2.45ドルの価格で取得しました。これは水曜日のロイターの報告によるものです。この取得は、Bitfarmsの約11.63%にものぼる既存の持株割合に加えられたものです。
RiotはBitfarmsの企業統治に関する懸念から、Bitfarmsの取締役会に独立取締役を含めるための特別株主総会の開催を計画していると述べています。
この動きは、先日Kerrisdale CapitalがRiot Platformsの空売りポジションを発表し、結果としてRiotの株価が9%下落したという発表に続くものです。
さらに、Riot PlatformsはKerrisdale Capitalによる空売り報告の対象になりました。Kerrisdale Capitalは、Riotの株に対してネガティブな見解を示しています。この騒動がRiot Platformsの株式の変動性に追加されました。
株価動向：水曜日の取引の中で、Riot Platformsの株は1株9.650ドルで0.21%下落し、<a href="https://pro.benzinga.com/dashboard?_gl=1#380nj0&#x2A;_ga&#x2A;MTYyMDYzMDIyNi4xLjEuMS4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">Benzinga Proのデータ</a>によると、この日の取引を終えました。Bitfarmsの株は1株2.510ドルで4.15%上昇し、この日の取引を終えました

Comments

Riot Platforms

ニュース

最新ニュース Riot Platforms (NASDAQ:RIOT) 株価情報

木曜日, 6 06, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル